Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moExternal Resources
ACITRETIN by Viatris is clinical pharmacology the mechanism of action of acitretin is unknown. Approved for severe psoriasis in adults. First approved in 2015.
Drug data last refreshed 26m ago
CLINICAL PHARMACOLOGY The mechanism of action of acitretin is unknown. Pharmacokinetics: Absorption: Oral absorption of acitretin is optimal when given with food. For this reason, acitretin was given with food in all of the following trials. After administration of a single 50-mg oral dose of…
Worked on ACITRETIN at Viatris? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
Combining Acitretin and Efalizumab in the Therapy of Chronic Plaque Psoriasis
Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation
Treatment of Psoriasis Using Acitretin in HIV-Positive Patients
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo